Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Colorcon
Medtronic
Baxter
Dow

Last Updated: December 7, 2021

DrugPatentWatch Database Preview

BAUSCH Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for BAUSCH
International Patents:508
US Patents:90
Tradenames:140
Ingredients:114
NDAs:161
Patent Litigation for BAUSCH: See patent lawsuits for BAUSCH

Drugs and US Patents for BAUSCH

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-003 May 8, 2006 DISCN Yes No 7,919,483 ⤷  Try it Free ⤷  Try it Free
Bausch VASERETIC enalapril maleate; hydrochlorothiazide TABLET;ORAL 019221-001 Oct 31, 1986 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free
Bausch D.H.E. 45 dihydroergotamine mesylate INJECTABLE;INJECTION 005929-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes ⤷  Try it Free ⤷  Try it Free
Bausch BRINZOLAMIDE brinzolamide SUSPENSION/DROPS;OPHTHALMIC 204884-001 Aug 18, 2021 AB RX No No ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BAUSCH

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb ALREX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020803-001 Mar 9, 1998 5,540,930*PED ⤷  Try it Free
Bausch CARDIZEM CD diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020062-005 Aug 24, 1999 5,286,497 ⤷  Try it Free
Bausch DIASTAT diazepam GEL;RECTAL 020648-003 Jul 29, 1997 5,462,740 ⤷  Try it Free
Bausch And Lomb ZYLET loteprednol etabonate; tobramycin SUSPENSION/DROPS;OPHTHALMIC 050804-001 Dec 14, 2004 4,996,335*PED ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAUSCH drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Gel 0.77% ➤ Subscribe 2006-05-10
➤ Subscribe Extended-release Tablets 174 mg ➤ Subscribe 2009-09-28
➤ Subscribe Lotion 0.1% ➤ Subscribe 2016-08-31
➤ Subscribe Extended-release Tablets 522 mg ➤ Subscribe 2009-12-24
➤ Subscribe Cream 3.75% ➤ Subscribe 2012-08-08
➤ Subscribe Extended-release Tablets 420 mg ➤ Subscribe 2005-04-25
➤ Subscribe For Inhalation Solution 6 gm/vial ➤ Subscribe 2014-05-22
➤ Subscribe Extended-release Tablet 55 mg and 80 mg ➤ Subscribe 2010-12-02
➤ Subscribe Rectal Gel 5 mg/mL, 4mL pre-filled syringe ➤ Subscribe 2008-12-08
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 2004-09-21
➤ Subscribe Gel 1.2%/2.5% ➤ Subscribe 2012-12-20
➤ Subscribe Ophthalmic Solution 0.07% ➤ Subscribe 2013-07-26
➤ Subscribe Capsules 75 mg ➤ Subscribe 2011-06-06
➤ Subscribe Vaginal Gel 0.75% ➤ Subscribe 2004-09-02
➤ Subscribe Topical Solution 10% ➤ Subscribe 2018-06-06
➤ Subscribe Cream 5% ➤ Subscribe 2006-10-17
➤ Subscribe Extended-release Tablets 348 mg ➤ Subscribe 2009-09-24
➤ Subscribe Cream 0.10% ➤ Subscribe 2008-01-31
➤ Subscribe Extended-release Tablets 120 mg, 180 mg, 240 mg, 300 mg and 360 mg ➤ Subscribe 2005-08-30
➤ Subscribe Cream 2.5% ➤ Subscribe 2014-06-17
➤ Subscribe Extended-release Tablets 65 mg and 115 mg ➤ Subscribe 2009-11-19
➤ Subscribe Rectal Gel 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL ➤ Subscribe 2004-03-23
➤ Subscribe Extended-release Tablet 105 rng ➤ Subscribe 2010-12-28
➤ Subscribe Rectal Gel 5 mg/mL, 2mL pre-filled syringe ➤ Subscribe 2008-12-23
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 2012-10-19
➤ Subscribe Gel 1.2%/3.75% ➤ Subscribe 2015-09-30
➤ Subscribe Ophthalmic Solution 1.5% ➤ Subscribe 2013-09-09
➤ Subscribe Gel 1.2%/0.025% ➤ Subscribe 2010-12-17
Premature patent expirations for BAUSCH

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
⤷  Try it Free ⤷  Try it Free

Supplementary Protection Certificates for BAUSCH Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1631293 2014/041 Ireland ⤷  Try it Free PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
0509752 2000C/001 Belgium ⤷  Try it Free PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
2822954 18C1035 France ⤷  Try it Free PRODUCT NAME: BICTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER BICTEGRAVIR DE SODIUM; REGISTRATION NO/DATE: EU/1/18/1289 20180625
1304992 CR 2013 00053 Denmark ⤷  Try it Free PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Express Scripts
Merck
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.